Orsini, Alessandro
Ferrari, Daniele
Riva, Antonella
Santangelo, Andrea
Macrì, Angelo
Freri, Elena
Canafoglia, Laura
D’Aniello, Alfredo
Di Gennaro, Giancarlo
Massimetti, Gabriele
Minetti, Carlo
Zara, Federico
Michelucci, Roberto
Tumber, Anupreet
Vincent, Ajoy
Minassian, Berge Arakel
Striano, Pasquale http://orcid.org/0000-0002-6065-1476
Article History
Received: 20 November 2021
Revised: 12 January 2022
Accepted: 13 January 2022
First Online: 20 February 2022
Declarations
:
: P.S has served on a scientific advisory board for the Italian Agency of the Drug (AIFA); has received honoraria from GW pharma, Kolfarma s.r.l, and Eisai Inc.; and has received research support from the Italian Ministry of Health and Fondazione San Paolo. G. DiG. has participated in advisory boards and pharmaceutical industry-sponsored symposia for Arvelle, BIAL, Eisai, LivaNova, Lucsofarmaco and UCB Pharma. A.D’A. has participated in pharmaceutical industry-sponsored clinicaltrials for UCB Pharma and symposia for Eisai, Lusofarmaco and UCB Pharma. A.R has received honoraria from Kolfarma s.r.l and Proveca Pharma Ltd. All the authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.
: This study has been approved by the institutional review boards and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.